Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2010. Refer to TA185: Trabectedin for the treatment of advanced soft tissue sarcoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | trabectedin (Yondelis®) | |
| Formulation | powder for concentrate for solution for infusion | |
| Reference number | 318 | |
| Indication | Treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents |
|
| Company | Pharma Mar SA | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| Advice number | 1408 | |
| NMG meeting date | 16/07/2008 | |
| AWMSG meeting date | 13/08/2008 | |
| Ratification by Welsh Government | 29/09/2008 | |
| Date of issue | 16/10/2008 | |
| NICE guidance | TA185: Trabectedin for the treatment of advanced soft tissue sarcoma |
|